New York, NY 10/30/18—According to Bloomberg, Thermo Fisher Scientific is evaluating the possible sale of its anatomical pathology business. Citing anonymous sources, Bloomberg reports that the sale could be worth $1 billion. Thermo Fisher provided no comment and has made no decision.

Thermo Fisher’s anatomical pathology business, 1 of the 6 businesses that make up the company’s Specialty Diagnostics unit, represented 9% of the unit sales in 2017, or over $300 million, according to an investor presentation from earlier this year. Bloomberg reported that EBITDA for the business totaled $85 million. Products sold by the business serve histology, cytology and hematology applications.